Evidence map›Paper›PMID 38496574›Full record

ArticleResearch square2024

Classification of Schizophrenia, Bipolar Disorder and Major Depressive Disorder with Comorbid Traits and Deep Learning Algorithms.

Xiangning Chen, Yimei Liu, Joan Cue, Mira Han Vishwajit Nimgaonkar, Daniel Weinberger, Shizhong Han, Zhongming Zhao, Jingchun Chen

Abstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Xiangning ChenThe university of Texas Health Science Center at Houston.
Yimei LiuDirector and CEO, Lieber Institute for Brain Development, Johns Hopkins School of Medicine: Departments of Psychiatry, Neurology, Neuroscience and Genetic Medicine.
Joan CueDirector and CEO, Lieber Institute for Brain Development, Johns Hopkins School of Medicine: Departments of Psychiatry, Neurology, Neuroscience and Genetic Medicine.
Mira Han Vishwajit NimgaonkarDirector and CEO, Lieber Institute for Brain Development, Johns Hopkins School of Medicine: Departments of Psychiatry, Neurology, Neuroscience and Genetic Medicine.
Daniel WeinbergerDirector and CEO, Lieber Institute for Brain Development, Johns Hopkins School of Medicine: Departments of Psychiatry, Neurology, Neuroscience and Genetic Medicine.ORCID 0000-0003-2409-2969
Shizhong HanLieber Institute for Brain Development; Johns Hopkins School of Medicine Department of Psychiatry and Behavioral Sciences.ORCID 0000-0002-5114-6742
Zhongming ZhaoUniversity of Texas HSC Houston.ORCID 0000-0002-3477-0914

Funding

The Genome Analysis and Sequencing Pipeline (GASP)P20GM121325 · NIGMS · UNIVERSITY OF NEVADA LAS VEGAS · PI CHEN, JINGCHUN · 2018 to 2022
$11.5M
A Large-Scale Schizophrenia Association Study in SwedenR01MH077139 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SULLIVAN, PATRICK F · 2007 to 2018
$9.9M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059571 · NIMH · UNIVERSITY OF CHICAGO · PI GEJMAN, PABLO V. · 1999 to 2007
$8.0M
Transforming dbGaP genetic and genomic data to FAIR-ready by artificial intelligence and machine learning algorithmsR01LM012806 · NLM · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Zhongming Zhao · 2017 to 2026
$3.7M
2/2 Large-Scale Genetic Studies of Schizophrenia in SwedenR01MH095034 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI STAHL, ELI A · 2012 to 2019
$3.6M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH060879 · NIMH · WASHINGTON UNIVERSITY · PI CLONINGER, C. ROBERT · 1999 to 2006
$2.7M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059586 · NIMH · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI SILVERMAN, JEREMY M. · 1999 to 2006
$1.9M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH061675 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI LEVINSON, DOUGLAS FREDERICK · 1999 to 2007
$1.8M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059587 · NIMH · EMORY UNIVERSITY · PI AMIN, FAROOQ · 1999 to 2006
$1.8M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059565 · NIMH · UNIVERSITY OF COLORADO DENVER · PI FREEDMAN, ROBERT · 1999 to 2006
$1.7M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059588 · NIMH · UNIVERSITY OF QUEENSLAND · PI MOWRY, BRYAN JOHN · 1999 to 2006
$1.4M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH060870 · NIMH · UNIVERSITY OF CALIFORNIA IRVINE · PI BYERLEY, WILLIAM · 1999 to 2006
$1.3M
NIGMS NIH HHS P20 GM121325NIMH NIH HHS R01 MH059565NIMH NIH HHS R01 MH059566NIMH NIH HHS R01 MH059571NIMH NIH HHS R01 MH059586NIMH NIH HHS R01 MH059587NIMH NIH HHS R01 MH059588NIMH NIH HHS R01 MH060870NIMH NIH HHS R01 MH060879NIMH NIH HHS R01 MH061675NIMH NIH HHS R01 MH067257NIMH NIH HHS R01 MH074027NIMH NIH HHS R01 MH077139NIMH NIH HHS R01 MH095034NLM NIH HHS R01 LM012806
6 · The paper itself

Abstract

Recent GWASs have demonstrated that comorbid disorders share genetic liabilities. But whether and how these shared liabilities can be used for the classification and differentiation of comorbid disorders remains unclear. In this study, we use polygenic risk scores (PRSs) estimated from 42 comorbid traits and the deep neural networks (DNN) architecture to classify and differentiate schizophrenia (SCZ), bipolar disorder (BIP) and major depressive disorder (MDD). Multiple PRSs were obtained for individuals from the schizophrenia (SCZ) (cases = 6,317, controls = 7,240), bipolar disorder (BIP) (cases = 2,634, controls 4,425) and major depressive disorder (MDD) (cases = 1,704, controls = 3,357) datasets, and classification models were constructed with and without the inclusion of PRSs of the target (SCZ, BIP or MDD). Models with the inclusion of target PRSs performed well as expected. Surprisingly, we found that SCZ could be classified with only the PRSs from 35 comorbid traits (not including the target SCZ and directly related traits) (accuracy 0.760 ± 0.007, AUC 0.843 ± 0.005). Similar results were obtained for BIP (33 traits, accuracy 0.768 ± 0.007, AUC 0.848 ± 0.009), and MDD (36 traits, accuracy 0.794 ± 0.010, AUC 0.869 ± 0.004). Furthermore, these PRSs from comorbid traits alone could effectively differentiate unaffected controls, SCZ, BIP, and MDD patients (average categorical accuracy 0.861 ± 0.003, average AUC 0.961 ± 0.041). These results suggest that the shared liabilities from comorbid traits alone may be sufficient to classify SCZ, BIP and MDD. More importantly, these results imply that a data-driven and objective diagnosis and differentiation of SCZ, BIP and MDD may be feasible.

Identifiers

PMID38496574
PMCPMC10942564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.